Holista Colltech Limited (AU:HCT)
ASX:HCT
Want to see AU:HCT full AI Analyst Report?
Top Page
Holista Colltech Limited
(Sydney:HCT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
▼(-33.33% Downside)
Action:ReiteratedDate:05/08/26
The score is held down primarily by weak financial performance—revenue contraction, deeper losses, and persistent negative operating/free cash flow—along with elevated leverage despite equity turning positive. Technicals are only mildly supportive in the near term, while valuation remains unattractive/unclear due to negative earnings and no dividend yield provided.
Positive Factors
Diversified revenue streams
Multiple commercial channels (finished products, ingredient supply, contract manufacturing and licensing) create durable optionality. This reduces single-customer concentration, allows revenue capture at different margin points and supports resilience as product adoption or channels evolve over months.
Negative Factors
Persistent negative cash generation
Consistent negative operating and free cash flow indicate ongoing cash burn and limited internal funding for growth or working capital. Over several months this forces reliance on external financing, increasing dilution or debt and constraining the company's ability to scale or absorb shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Multiple commercial channels (finished products, ingredient supply, contract manufacturing and licensing) create durable optionality. This reduces single-customer concentration, allows revenue capture at different margin points and supports resilience as product adoption or channels evolve over months.
Read all positive factors
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.91M
Dividend YieldN/A
Average Volume (3M)72.05K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth2.96%
EPS Growth-866.67%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding367,834,350
10 Day Avg. Volume123,924
30 Day Avg. Volume72,050
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)28.04
Price to Sales (P/S)5.45
P/FCF Ratio-20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Holista Colltech Limited Business Overview & Revenue Model
Company Description
Holista CollTech Limited operates as a biotech company in Australia, Malaysia, and the United States. The company operates through Supplements, Ovine Collagen, Infection control Solutions, and Food Ingredients segments. It manufactures and wholesa...
How the Company Makes Money
HCT makes money primarily by commercializing its health and wellness offerings through the sale of products and/or ingredients to customers (for example, consumers, distributors, or business customers depending on the channel). Revenue is generate...
Holista Colltech Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.76M | 5.60M | 5.95M | 8.24M | 8.02M |
| Gross Profit | 770.25K | 87.03K | 370.06K | 4.24M | 1.31M |
| EBITDA | -788.46K | 304.37K | -4.52M | -1.02M | -957.40K |
| Net Income | -948.92K | -84.21K | -4.81M | -1.45M | -1.26M |
Balance Sheet | |||||
| Total Assets | 5.87M | 3.34M | 3.35M | 5.52M | 6.93M |
| Cash, Cash Equivalents and Short-Term Investments | 2.16M | 21.72K | 59.77K | 117.53K | 1.21M |
| Total Debt | 1.59M | 1.77M | 1.57M | 1.22M | 890.32K |
| Total Liabilities | 6.29M | 6.71M | 6.74M | 3.96M | 3.95M |
| Stockholders Equity | 1.12M | -1.73M | -1.97M | 2.83M | 4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.52M | -1.02M | -411.67K | -1.19M | -1.72M |
| Operating Cash Flow | -1.35M | -1.01M | -407.12K | -1.11M | -1.68M |
| Investing Cash Flow | -176.36K | 692.12K | -46.70K | -105.69K | 50.35K |
| Financing Cash Flow | 3.65M | 143.75K | 418.42K | 120.85K | 109.49K |
Holista Colltech Limited Technical Analysis
Negative
0.09
Price Trends
0.07
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
10.04
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 10.04 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.
Holista Colltech Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$35.84M | 22.20 | -53.68% | ― | -12.46% | 44.05% | |
44 Neutral | AU$23.91M | -12.65 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$6.62M | -3.85 | -35.12% | ― | 96.60% | 67.50% | |
41 Neutral | AU$10.22M | -1.62 | -44.35% | ― | -32.09% | 34.85% | |
39 Underperform | AU$5.77M | -0.92 | -92.72% | ― | 5.79% | 29.75% |
* Consumer Defensive Sector Average
AU:HCT
Holista Colltech Limited
0.07
0.02
51.16%
AU:WNX
Wellnex Life Ltd
0.08
-0.20
-71.79%
AU:EVE
EVE Health Group Limited
0.03
>-0.01
-3.33%
AU:OMG
Forbidden Foods Ltd
0.01
-0.01
-50.00%
AU:MBH
Maggie Beer Holdings Ltd.
0.08
0.03
48.15%
Holista Colltech Limited Corporate Events
Holista seals joint venture to build WA ovine nano-collagen plant
May 4, 2026
Holista Colltech Limited has entered a binding 50:50 joint venture with Hong Kong–listed Swang Chai Chuan Limited to fund, develop, and operate an ovine nano-collagen production facility in Collie, Western Australia, via Ovicoll Pty Ltd. SCC...
Holista Colltech holds revenue steady but posts cash outflow in March quarter
Apr 28, 2026
Holista Colltech reported quarterly revenue of about $1.49 million for the period ended 31 March 2026, with approximately $1.47 million contributed by its core supplements segment, underscoring resilient customer demand. Smaller contributions came...
Holista Colltech Sets 2026 AGM and Urges Timely Proxy Voting
Apr 24, 2026
Holista Colltech Limited has scheduled its Annual General Meeting for 2:00 p.m. AWST on Monday, 25 May 2026, to be held at Stantons International, 40 Kings Park Road, West Perth, Western Australia. Shareholders are encouraged to participate either...
Holista Colltech Sets 2026 AGM to Confirm Directors and Expand Capital-Raising Capacity
Apr 24, 2026
Holista Colltech Limited has called its annual general meeting for 25 May 2026 in West Perth, where shareholders will review the company’s financial statements for the year ended 31 December 2025 and vote on the non-binding adoption of the r...
Holista Colltech Trading Reinstated on ASX After Legal Matter Update
Apr 22, 2026
Trading in Holista Colltech Limited shares on the ASX has been reinstated following the company’s release of an announcement about its legal matter with ProImmune Company LLC. The lifting of the suspension restores liquidity for shareholders...
Holista Colltech Strikes Discounted Settlement After US$2.06m ProImmune Judgment
Apr 22, 2026
Holista Colltech has been ordered by the Supreme Court of Western Australia to satisfy a US$2.06 million US judgment obtained by The ProImmune Company over alleged breaches of minimum performance obligations under distribution agreements for Immun...
Holista Colltech Shares Remain Suspended Amid Legal Matter and ASX Compliance Review
Apr 14, 2026
Holista Colltech Limited’s shares remain suspended from trading on the ASX after the company failed to provide an update on an ongoing legal matter with ProImmune Company LLC. The suspension follows an initial trading halt requested on 8 Apr...
Holista Colltech Requests ASX Suspension Pending Legal Matter Update
Apr 9, 2026
Holista Colltech Limited has requested and been granted a voluntary suspension of trading in its ordinary shares on the ASX under Listing Rule 17.2, pending the release of an announcement regarding a legal matter involving ProImmune Company LLC. T...
Holista Colltech Seeks Trading Halt Ahead of Legal Matter Update
Apr 8, 2026
Holista Colltech Limited has requested an immediate trading halt in its ordinary shares on the ASX, with the halt to remain in place until either normal trading resumes on 10 April 2026 or the company releases a pending announcement. The company s...
Holista Colltech Files Appendix 4G, Confirms ASX Governance Compliance
Mar 29, 2026
Holista Colltech has lodged its latest Appendix 4G with the ASX, confirming that its corporate governance statement for the year ended 31 December 2025 is contained within its annual report and is current as of 27 March 2026. The filing outlines t...
Holista Colltech refreshes board and outlines 2025 governance structure
Mar 29, 2026
Holista Colltech Limited has released its annual report for the year ended 31 December 2025, outlining its refreshed board and governance structure. The company appointed a new CEO, Leong Man Loong, in July 2025 and added three non-executive direc...
Holista Colltech lifts revenue and margins but one-off legal costs drive FY2025 loss
Feb 27, 2026
Holista Colltech reported a 3% rise in full-year 2025 revenue to about $5.8 million, driven mainly by an 11.4% increase in dietary supplements sales and favourable foreign exchange movements, despite a sharp fall in food ingredients revenue. Gross...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.